Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Archives of Neurology

• Publication date

  2004-12-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1001/ARCHNEUR.61.12.1920PMID 15596613
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An [ 18 F]dopa-PET and clinical study of the rate of progression in Parkinson's disease

  2005cited by this paper
• Apoptosis in Parkinson's disease: Signals for neuronal degradation

  2003cited by this paper
• Altered proteasomal function in sporadic Parkinson's disease.

  2003cited by this paper
• Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration

  2003cited by this paper
• Molecular Pathways of Neurodegeneration in Parkinson's Disease

  2003cited by this paper
• Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones?

  2002cited by this paper
• Neurodegenerative tauopathies.

  2001cited by this paper
• Apoptosis in the nervous system

  2000cited by this paper
• Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism

  2000influential reference
• Parkinson's disease is not one disease.

  2000cited by this paper
• In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

  2000cited by this paper
• Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease.

  2000cited by this paper
• Oxidative Stress Leading to Loss of Critical Proteases in Alzheimer's Disease: An Alternative View of the Etiology of AD

  2000cited by this paper
• 'Like a thief in the night': the selectivity of degeneration in Parkinson's disease.

  1999cited by this paper
• Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure

  1999cited by this paper
• Mitochondria in the etiology and pathogenesis of parkinson's disease

  1998cited by this paper
• Determinants of neuronal vulnerability in neurodegenerative diseases

  1998cited by this paper
• Kinetic Evaluation of [11C]Dihydrotetrabenazine by Dynamic PET: Measurement of Vesicular Monoamine Transporter

  1996cited by this paper
• Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging

  1996cited by this paper
• Modern Applied Statistics with S-Plus.

  1996cited by this paper
• The Vesicular Monoamine Transporter, in Contrast to the Dopamine Transporter, Is Not Altered by Chronic Cocaine Self-Administration in the Rat

  1996cited by this paper
• An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

  1996cited by this paper
• The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.

  1995cited by this paper
• Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1995cited by this paper
• The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases.

  1995cited by this paper
• Patterns of Asymmetry Do Not Change Over the Course of Idiopathic Parkinsonism

  1995cited by this paper
• Aging, energy, and oxidative stress in neurodegenerative diseases

  1995cited by this paper
• Clinical observations on the rate of progression of idiopathic parkinsonism.

  1994cited by this paper
• Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions

  1994cited by this paper
• Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease

  1992influential reference
• Core assessment program for intracerebral transplantations (CAPIT)

  1992cited by this paper
• Criteria for diagnosing Parkinson's disease

  1992cited by this paper
• Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease

  1992cited by this paper
• Ageing and Parkinson's disease: substantia nigra regional selectivity.

  1991influential reference
• Rate of cell death in parkinsonism indicates active neuropathological process

  1988influential reference
• Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

  1988cited by this paper
• Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

  1985cited by this paper

• Spatiotemporal patterns of putaminal dopamine processing in Parkinson’s disease: A multi-tracer positron emission tomography study

  2022cites this paper
• Patterns of striatal dopamine depletion and motor deficits in de novo Parkinson’s disease

  2022cites this paper
• Comparisons of vesicular monoamine transporter type 2 signals in Parkinson's disease and Parkinsonism secondary to carbon monoxide poisoning.

  2021cites this paper
• Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review

  2021cites this paper
• NRM 2021 Abstract Booklet

  2021cites this paper
• PET Imaging of Vesicular Monoamine Transporters

  2020cites this paper
• The Pattern of Striatal Dopamine Depletion as a Prognostic Marker in De Novo Parkinson Disease

  2018cites this paper
• Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

  2018cites this paper
• Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson’s disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging

  2017cites this paper
• Stereological Evaluation of the Brains in Patients with Parkinson’s disease Compared to Controls

  2017cites this paper
• Stage-dependent loss of cortical gyrification as Parkinson disease “unfolds”

  2016cites this paper
• The pattern of gray matter atrophy in Parkinson’s disease differs in cortical and subcortical regions

  2015cites this paper
• Automated Neuromelanin Imaging as a Diagnostic Biomarker for Parkinson's Disease

  2015cites this paper
• Radioligands for imaging vesicular monoamine transporters

  2014cites this paper
• Functional neuroimaging in the diagnosis of patients with parkinsonism: Update and recommendations for clinical use

  2014cites this paper
• [Functional neuroimaging in the diagnosis of patients with Parkinsonism: Update and recommendations for clinical use].

  2014cites this paper
• Novel spatial analysis method for PET images using 3D moment invariants: Applications to Parkinson's disease

  2013cites this paper
• The Nature of Progression in Parkinson’s Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects Modelling

  2013cites this paper
• Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice.

  2013cites this paper
• Imaging of VMAT2 binding sites in the brain by (18)F-AV-133: the effect of a pseudo-carrier.

  2012cites this paper
• Imaging nigral pathology and clinical progression in Parkinson's disease

  2012cites this paper
• Quantitative analysis of binding sites for 9‐fluoropropyl‐(+)‐dihydrotetrabenazine ([18F]AV‐133) in a MPTP‐lesioned PD mouse model

  2012cites this paper
• Parkinson’s Disease: Where Are We?

  2012cites this paper
• Neuroimaging: Current role in detecting pre‐motor Parkinson's disease

  2012cites this paper
• Subtle rapid eye movement sleep abnormalities in presymptomatic spinocerebellar ataxia type 2 gene carriers

  2011influential citation
• A pilot open‐label trial of zonisamide in Unverricht‐Lundborg disease

  2011influential citation
• Rhinorrhea: A common nondopaminergic feature of Parkinson's disease

  2011influential citation
• Subregional 6-[18F]fluoro-ʟ-m-tyrosine Uptake in the Striatum in Parkinson's Disease

  2011cites this paper
• Functional neuroimaging in Parkinson's disease.

  2011cites this paper
• Residual striatal dopaminergic nerve terminals in very long‐standing Parkinson's disease: A single photon emission computed tomography imaging study

  2011influential citation
• Evolution of brain imaging instrumentation.

  2011cites this paper
• Severe dystonic encephalopathy without hyperphenylalaninemia associated with an 18‐bp deletion within the proximal GCH1 promoter

  2011influential citation
• Subregional 6-[ 18 F ] fluoro-Lm-tyrosine Uptake in the Striatum in Parkinson ’ s Disease

  2011cites this paper
• Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease

  2011cites this paper
• Central oscillators in a patient with neuropathic tremor: Evidence from intraoperative local field potential recordings

  2011influential citation
• Oligoclonal bands in cerebrospinal fluid in patients with Tourette's syndrome

  2011influential citation
• fluoro-Lm-tyrosine Uptake in the Striatum in Parkinson ’ s Disease

  2010cites this paper
• Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study.

  2010cites this paper
• (18)F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons.

  2010cites this paper
• Whole-Body Biodistribution and Radiation Dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): A Novel Vesicular Monoamine Transporter 2 Imaging Agent

  2010cites this paper
• EFECTO DE LA ADMINISTRACIÓN CRÓNICA DE LEVODOPA SOBRE LA ACTIVIDAD FUNCIONAL DE LA VÍA NIGROESTRIADA EN MACACOS CON PARKINSONISMO INDUCIDO POR MPTP

  2010cites this paper
• Asymmetrical lateral ventricular enlargement in Parkinson’s disease

  2009cites this paper
• Dopaminergic function and progression of Parkinson's disease: PET findings.

  2009cites this paper
• Synthesis and evaluation of 2-amino-dihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2.

  2009cites this paper
• Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study.

  2009cites this paper
• Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease

  2008cites this paper
• Development of a stable, early stage unilateral model of Parkinson's disease in middle-aged rhesus monkeys.

  2008cites this paper
• Introduction to: Neurotoxin-based Nonhuman Primate Models of Parkinson's Disease

  2008cites this paper
• Cutting-edge brain imaging with positron emission tomography.

  2007cites this paper
• Cutting-Edge Brain Imaging with Positron Emission Tomography.

  2007cites this paper
• Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease.

  2007cites this paper
• Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.

  2007cites this paper
• Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.

  2006cites this paper
• Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.

  2006cites this paper
• Age at menopause predicts age at onset of Parkinson's disease

  2006cites this paper
• Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: A multi-tracer PET study

  2006cites this paper
• Striatal dopaminergic neurons are lost with Parkinson's disease progression

  2006cites this paper
• Hot spots: Can positron emission tomography offer insights into the pathogenesis of PD?

  2005cites this paper